| Name | Title | Contact Details |
|---|
Micro Invasive Technology is a Pomfret Center, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medisafe® is the leading Personalized Medication Management Platform helping patients stay on top of all their medications. Way more than a pill organizer (although it`s that, too), Medisafe makes it easy to adhere to the most complicated medication schedule, so wondering, “Did I take this already?” is a thing of the past. But that`s just the beginning. Medisafe connects users to their family (and soon, their doctors) for support, encouragement and expertise. It learns about each user`s unique situation, so it can deliver custom notifications for appointments and refills, medication updates, personalized health recommendations and discounts to help you stay organized, informed and on budget. And it tracks progress correlated with measurements like blood pressure and glucose levels to show the direct health benefit of taking meds as prescribed. By addressing all the major root causes for failing to take medications as prescribed, Medisafe improves patient satisfaction and quality of care and eliminates admissions and outpatient visits resulting from incorrect or missed doses. Medisafe arms providers and payers with information about patient compliance and related behaviors, so they can focus on the most pressing situations at any time. Understanding which patients are most at risk (and threatening to add avoidable strain to an overburdened healthcare system) helps all stakeholders in the care continuum use limited time and resources as efficiently as possible. Medisafe currently has more than 7 million users across iOS and Android smartphones and tablets, who have recorded over 4 billion medication doses taken correctly. Nearly 250,000 users have rated the app an average of 4.6 out of 5 stars in the iTunes and Google Play app stores.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
Design Clinicals is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Tukwila, WA. To find more information about Design Clinicals, please visit www.designclinicals.com
West Virginia Primary Care Association is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.